Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma.
Keywords: Abiraterone; Androgen deprivation treatment; Cabazitaxel; Castration-resistant prostate cancer; Docetaxel; Enzalutamide; Hormone-sensitive advanced prostate cancer; Radium 223.